Glucagon-like peptide-1 (GLP-1) receptor agonists

Go to algorithm

exp date isn't null, but text field is

MHRA advice: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued (June 2019) (www.gov.uk).

Refer to protocol for use of GLP-1 analogues.

LIRAGLUTIDE (First Line)

Therapy notes

First line once daily option.

Formulation

Injection, pre-filled pen 18mg/3mL

SEMAGLUTIDE (First Line)

Therapy notes

First line once weekly option.

Formulation

Solution for injection, pre-filled pen (Ozempic) 0·25mg, 0·5mg and 1mg

Formulation and dosage details

Formulation:

Tablets (Rybelsus) 3mg, 7mg and 14mg

Dosage:

Oral, once daily alternative to subcutaneous semaglutide - when subcutaneous route not suitable.

DULAGLUTIDE (Second Line)

Therapy notes

Second line once weekly option.

Formulation

Injection, pre-filled pen 750 micrograms/0·5mL, 1·5mg/0·5mL 

EXENATIDE

Therapy notes


MHRA advice: Exenatide (Byetta): risk of severe pancreatitis and renal failure (December 2014) (www.gov.uk).

  • Only for continued use in those already maintained on therapy.

Formulation

Injection, pre-filled pen 5 micrograms/dose, 10 micrograms/dose 

Formulation

Prolonged-release suspension for injection 2mg/pre-filled pen

Last reviewed: 11 February 2021

Approved By: TAM Subgroup